Edwards Lifesciences announced today that its Sapien M3 mitral valve replacement system received FDA approval for mitral ...

The Sapien M3 device is the first approved mitral regurgitation treatment to use a transseptal approach, Edwards said.

The US Food and Drug Administration has approved the Sapien M3 system for transseptal transcatheter mitral valve replacement (TMVR) for use in patients with symptomatic moderate-to-severe mitral ...

To get an idea of why investors and analysts are excited about Irvine-based Edwards Lifesciences Corp.’s latest heart valve, look to Europe. The company’s Sapien valve, which is inserted via a ...

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of ...

NYON, Switzerland--(BUSINESS WIRE)--Edwards Lifesciences today announced the launch in Europe of the SAPIEN 3 transcatheter pulmonary valve implantation (TPVI) system with Alterra adaptive prestent, ...

Sapien valve: about $110 million in 2009 sales in Europe Edwards Lifesciences Corp.’s Wall Street run is expected to continue into 2010. The Irvine maker of heart valves and related devices has been ...

After acquiring its developer last year, Edwards Lifesciences has now obtained a European approval for what it described as the world’s first transfemoral transcatheter mitral valve replacement ...

SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced ...

SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The ...